相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
Yemil Atisha-Fregoso et al.
ARTHRITIS & RHEUMATOLOGY (2021)
De novo lupus nephritis during treatment with belimumab
Ioannis Parodis et al.
RHEUMATOLOGY (2021)
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Jing He et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus
Erica Moore et al.
CURRENT OPINION IN RHEUMATOLOGY (2020)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections
Eri Katsuyama et al.
CELL REPORTS (2020)
Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: A systematic review and meta-analysis
Lanlan Ji et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials
Jeffery Wei Heng Koh et al.
LUPUS (2020)
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus
Lennard Ostendorf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
Sabih Ul Hassan et al.
FRONTIERS IN MEDICINE (2020)
PRECLINICAL EFFICACY OF R835, A NOVEL IRAK1/4 DUAL INHIBITOR, IN RODENT MODELS OF JOINT INFLAMMATION
C. Lamagna et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
AURORA PHASE 3 STUDY DEMONSTRATES VOCLOSPORIN STATISTICAL SUPERIORITY OVER STANDARD OF CARE IN LUPUS NEPHRITIS (LN)
C. Arriens et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
BIIB059, A HUMANIZED MONOCLONAL ANTIBODY TARGETING BDCA2 ON PLASMACYTOID DENDRITIC CELLS (PDC), SHOWS DOSE-RELATED EFFICACY IN THE PHASE 2 LILAC STUDY IN PATIENTS (PTS) WITH ACTIVE CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
V. Werth et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients
Chunmiao Zhao et al.
BMC IMMUNOLOGY (2019)
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis
Brad H. Rovin et al.
KIDNEY INTERNATIONAL (2019)
Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
Zhi-Wei Lai et al.
LANCET (2018)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Daniel J. Wallace et al.
LANCET (2018)
Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity
A. Ugarte et al.
LUPUS (2018)
Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors
Jacquelyn Nestor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
Ronald F. van Vollenhoven et al.
LANCET (2018)
Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis
Desmond Y. H. Yap et al.
JOURNAL OF RHEUMATOLOGY (2018)
New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab
Chrysanthi Staveri et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
B Cell-Based Treatments in SLE: Past Experience and Current Directions
Stamatis-Nick C. Liossis et al.
CURRENT RHEUMATOLOGY REPORTS (2017)
The Role of IL-23/IL-17 Axis in Lupus Nephritis
Zheng Zhang et al.
JOURNAL OF IMMUNOLOGY (2009)
Activation of Mammalian Target of Rapamycin Controls the Loss of TCRζ in Lupus T Cells through HRES-1/Rab4-Regulated Lysosomal Degradation
David R. Fernandez et al.
JOURNAL OF IMMUNOLOGY (2009)
Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus
David Fernandez et al.
ARTHRITIS AND RHEUMATISM (2006)
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
L Bennett et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
DT Boumpas et al.
ARTHRITIS AND RHEUMATISM (2003)
An open study of B lymphocyte depletion in systemic lupus erythematosus
MJ Leandro et al.
ARTHRITIS AND RHEUMATISM (2002)
分享论文
